Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sanofi Genzyme
Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
- Other Names / Subsidiaries
- ILEX Oncology, Inc.
- Sangstat Medical Corporation
- Genzyme Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.